Orforglipron: The New Oral GLP-1 Weight Loss Pill — What Trial Data Shows
The first oral GLP-1 receptor agonist specifically designed for weight loss is heading toward FDA approval — and it could change how millions of people manage obesity. Orforglipron, developed by Eli Lilly, is a once-daily pill that delivered an average weight loss of 27.3 pounds in clinical trials, rivaling the results of popular injectables like…